bamlanivimab monotherapy for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 outpatients meta-analysis
BLAZE-1 phase 2 (monotherapy) NCT04427501		RCT	bamlanivimab monotherapy	placebo	COVID 19 outpatients	some concern	101/156	inconclusive	no significant difference in viral load reduction was observed for bamlanivimab monotherapy at any dose
Bariola		OBS	bamlanivimab monotherapy	control	COVID 19 outpatients	NA	234/234	suggested	suggested 69 % decrease in hospitalization or death (PE) suggested 72 % decrease in hospitalization or death suggested 68 % decrease in hospitalization suggested 65 % decrease in hospitalization

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 outpatients meta-analysis